Wellbeing and Human Services Secretary Alex Azar declared on Wednesday that the US has marked an agreement with Pfizer for conveyance in December of the initial 100 million dosages of a COVID-19 antibody the pharmaceutical organization is attempting to create. The US could purchase another 500 million portions under the understanding, Azar said.

"Presently those would, obviously, must be protected and powerful" and be endorsed by the Food and Drug Administration, Azar said during an appearance on Fox News.

Pfizer Inc. what's more, BioNTech SE declared independently that the understanding is with HHS and the Defense Department for an antibody competitor the organizations are growing together.

The understanding is a piece of President Donald Trump's Operation Warp Speed immunization program, under which numerous COVID-19 antibodies are being grown at the same time. The program expects to convey 300 million portions of a sheltered and viable COVID-19 antibody by January 2021, as per HHS.

Under the activity, the legislature will speed improvement and purchase antibodies — before they are esteemed sheltered and powerful — with the goal that the medicine can be close by and immediately circulated once the FDA endorses or approves its crisis use.

Pfizer and BioNTech said the US will pay $1.95 endless supply of the initial 100 million dosages, following FDA approval or endorsement.

Azar said the agreement with Pfizer and BioNTech brings to five the quantity of potential coronavirus immunizations that are being worked on.

Trump said Tuesday at a preparation that "the immunizations are coming, and they're coming a great deal sooner than anybody suspected conceivable, by years." But different nations are likewise scrambling to get their hands on an antibody for COVID-19, which has killed in excess of 617,000 individuals, as indicated by a count kept by Johns Hopkins University.

Almost 4 million Americans have been contaminated by the new coronavirus and in any event 142,000 have kicked the bucket from COVID-19, the malady it causes, as indicated by Johns Hopkins.

England declared Monday it had tied down access to another 90 million test COVID-19 immunizations made by Pfizer and others, a move a few campaigners cautioned could intensify a worldwide scramble by rich nations to store the world's constrained flexibly of COVID-19 antibodies.

About two dozen potential immunizations are in different phases of human testing around the world, with a bunch entering essential late-stage testing to demonstrate adequacy.